📗 Cite This Artifact
ID: hypothesis-h-e12109e3
Hypothesis
Tau-Independent Microtubule Stabilization via MAP6 Enhancement
Tau-Independent Microtubule Stabilization via MAP6 Enhancement starts from the claim that modulating MAP6 within the disease context of neurodegeneration can redirect a disease-relevant process.
EvidencePending (0%)📖 24 cit🗣 2 debates✓ 14 support✗ 5 oppose
✓ All Quality Gates Passed
🧪 Overview
Mechanistic Overview
Tau-Independent Microtubule Stabilization via MAP6 Enhancement starts from the claim that modulating MAP6 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "Tau-independent microtubule stabilization via MAP6 (also known as STOP protein — Stable Tubule Only Polypeptide) enhancement proposes compensating for tau loss-of-function by upregulating an alternative microtubule-stabilizing protein. This strategy addresses a critical but underappreciated aspect of tauopathies: while pathological tau aggregation receives therapeutic attention, the loss of tau's normal microtubule-stabilizing function equally contributes to neurodegeneration through cytoskeletal collapse, axonal transport failure, and dendritic spine loss. The Tau Loss-of-Function Problem Tau's physiological role is to stabilize microtubules by binding along their lateral surface, promoting polymerization and preventing catastrophic depolymerization....
Mechanistic Overview
Tau-Independent Microtubule Stabilization via MAP6 Enhancement starts from the claim that modulating MAP6 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "Tau-independent microtubule stabilization via MAP6 (also known as STOP protein — Stable Tubule Only Polypeptide) enhancement proposes compensating for tau loss-of-function by upregulating an alternative microtubule-stabilizing protein. This strategy addresses a critical but underappreciated aspect of tauopathies: while pathological tau aggregation receives therapeutic attention, the loss of tau's normal microtubule-stabilizing function equally contributes to neurodegeneration through cytoskeletal collapse, axonal transport failure, and dendritic spine loss. The Tau Loss-of-Function Problem Tau's physiological role is to stabilize microtubules by binding along their lateral surface, promoting polymerization and preventing catastrophic depolymerization. In neurodegenerative tauopathies (Alzheimer's, PSP, CBD, FTD), tau progressively detaches from microtubules due to hyperphosphorylation at >40 sites, reducing its microtubule binding affinity by 90%. The detached hyperphosphorylated tau then aggregates into neurofibrillary tangles, but the primary functional consequence for the neuron is microtubule destabilization. The resulting microtubule loss is profound: - Axonal transport failure: Kinesin and dynein motors require intact microtubule tracks. Transport velocity of mitochondria, synaptic vesicles, and mRNA granules decreases 40-60% when tau-mediated stabilization is lost - Dendritic spine collapse: MAP2 (the primary dendritic MAP) partially compensates in dendrites, but entorhinal cortex layer II stellate neurons — the first affected in AD — show unusual dependence on tau for dendritic microtubule stability - Axon retraction: Without sufficient microtubule mass, axons retract from their targets. This disconnection (diaschisis) drives the progressive functional decline that correlates better with tau pathology than amyloid burden Why MAP6/STOP Protein? MAP6 is a cold-stable microtubule-associated protein predominantly expressed in neurons. It confers remarkable microtubule resistance to depolymerization through a mechanism distinct from tau: 1. Temperature-independent stabilization: While tau stabilizes microtubules primarily at 37°C, MAP6 also stabilizes them at 4°C — its cold-stability function is uniquely resistant to the conditions that promote microtubule disassembly. 2. Distinct binding mechanism: MAP6 contains Mn (microtubule N-terminal) and Mc (microtubule C-terminal) repeat modules that bind the microtubule lattice at sites partially overlapping with but distinct from tau binding sites. This means MAP6 can stabilize microtubules even on segments where tau has been displaced. 3. Resistance to tau-like pathological detachment: MAP6 binding is less dependent on phosphorylation regulation than tau. The kinases (GSK3β, CDK5) that drive tau detachment from microtubules have minimal effect on MAP6-microtubule binding. 4. Synaptic enrichment: MAP6 concentrates at synapses and in growth cones, precisely the compartments where microtubule stability is most critical and where tau loss creates the greatest vulnerability. MAP6 Decline in Neurodegeneration Despite its compensatory potential, MAP6 expression paradoxically declines in tauopathies. In AD hippocampus, MAP6 protein levels are reduced 35-50% compared to age-matched controls. This decline likely results from: - NF-κB-mediated transcriptional repression (neuroinflammation suppresses MAP6 promoter activity) - Calpain-mediated proteolysis (activated by calcium dysregulation) - miR-132 downregulation (miR-132 stabilizes MAP6 mRNA; its loss in AD accelerates MAP6 turnover) The simultaneous loss of both tau function and MAP6 expression creates a catastrophic microtubule deficit that overwhelms remaining MAPs (MAP1A, MAP1B, MAP2). Therapeutic Strategies for MAP6 Enhancement 1. HDAC inhibitors for MAP6 transcription: Sodium valproate and vorinostat increase MAP6 promoter acetylation and mRNA expression by 2-3 fold in neuronal cultures. The challenge is achieving selective MAP6 upregulation without broad epigenetic effects at therapeutic doses. 2. miR-132 replacement: miR-132 mimics (delivered via lipid nanoparticles or AAV) stabilize MAP6 mRNA and increase protein levels. miR-132 replacement also has independent neuroprotective effects through FOXO3 and SIRT1 pathway modulation. 3. Calpain inhibitors: Preventing MAP6 proteolytic degradation by inhibiting calpain 1/2. SNJ-1945 (calpain inhibitor) increases MAP6 protein levels by 40% in tau-depleted neurons and preserves microtubule mass. 4. Gene therapy: AAV-MAP6 delivery under a synapsin promoter provides direct MAP6 overexpression in neurons. In tau knockout mice, MAP6 overexpression rescues axonal transport, dendritic morphology, and LTP. 5. Combination with microtubule-stabilizing drugs: Epothilone D and related compounds (davunetide/NAP) stabilize microtubules pharmacologically. Combining exogenous stabilizers with MAP6 enhancement provides both immediate and sustained microtubule protection. Preclinical Evidence MAP6 knockout mice (STOP-null) exhibit severe synaptic deficits, including depleted synaptic vesicle pools, impaired LTP, and behavioral abnormalities mimicking schizophrenia symptoms. These deficits are rescued by MAP6 re-expression, demonstrating the protein's essential role in synaptic microtubule stability. In PS19 tauopathy mice, AAV-MAP6 hippocampal injection at pre-symptomatic ages preserves dendritic spine density (within 85% of wild-type), maintains axonal caliber in the perforant path, and delays cognitive decline onset by 3 months. Importantly, MAP6 overexpression does not prevent tau aggregation itself but protects the microtubule cytoskeleton from the functional consequences of tau loss. Epothilone D (0.3 mg/kg/week) in PS19 mice reduces axonal dystrophy by 50%, improves cognitive performance, and reduces tau pathology spread — possibly because intact microtubules facilitate tau degradation through enhanced autophagosome transport. Clinical Translation The layered therapeutic approach could proceed: (1) Near-term: calpain inhibitors (some with clinical safety data) to prevent MAP6 degradation; (2) Medium-term: miR-132 replacement therapy (oligonucleotide platform); (3) Longer-term: MAP6-targeted gene therapy. Biomarkers include CSF MAP6 levels (ELISA available), neurofilament light chain (microtubule breakdown marker), and DTI-MRI measurements of white matter integrity reflecting axonal microtubule status. Challenges and Risk Mitigation Challenge 1: MAP6 Overexpression Toxicity. Excessive microtubule stabilization can impair axonal branching and synaptic plasticity that depends on dynamic microtubule rearrangements. Mitigation: Use activity-dependent promoters (Arc, c-Fos) for MAP6 gene therapy to provide endogenous feedback control. Target MAP6 levels to 150-200% of normal rather than maximal overexpression. Monitor synaptic plasticity measures in preclinical studies. Challenge 2: Specificity of Calpain Inhibition. Calpain cleaves hundreds of substrates beyond MAP6. Non-selective calpain inhibition has broad effects on cellular signaling. Mitigation: Develop MAP6-targeted approaches as the primary strategy. Use calpain inhibitors only as bridge therapy. Investigate whether specific calpain isoforms preferentially cleave MAP6, enabling more selective inhibition. Challenge 3: Compensatory MAP Changes. Upregulating MAP6 may trigger compensatory downregulation of other MAPs through shared regulatory networks. Mitigation: Quantify all MAP family members in response to MAP6 manipulation in preclinical models. The combination with pharmacological microtubule stabilizers provides a parallel, MAP-independent stabilization mechanism. Challenge 4: Gene Therapy Delivery. AAV-based MAP6 delivery faces standard gene therapy challenges: immune responses to capsid proteins and inability to re-dose due to neutralizing antibodies. Mitigation: Use AAV9 or AAV-PHP.eB serotypes with established CNS tropism. Intrathecal delivery achieves wide CNS distribution with lower doses. For non-viral approaches, lipid nanoparticles carrying MAP6 mRNA could provide transient but repeatable dosing. Resource Requirements and Timeline - MAP6 enhancement mechanism validation: 18 months, $4-6M - AAV-MAP6 vector engineering and optimization: 24 months, $8-12M - miR-132 delivery platform development: 18 months, $6-10M - Preclinical efficacy in tauopathy models: 24 months, $10-15M - IND-enabling toxicology and biodistribution: 18 months, $8-12M - Phase 1/2a gene therapy trial: 36 months, $30-50M - Total to proof-of-concept: $70-105M over 8-10 years Competitive Landscape - Cortice Biosciences (CT-101): Microtubule-stabilizing compound targeting microtubule pharmacology directly rather than through MAP enhancement. - Ionis (IONIS-MAPTRx): Tau antisense oligonucleotide that reduces tau expression. Complementary to MAP6 enhancement. - Epothilone D (BMS-241027): Phase 1 small molecule microtubule stabilizer. Development paused due to toxicity concerns. Key differentiation: MAP6 enhancement is the only approach that compensates for tau loss-of-function by upregulating an endogenous substitute. MAP6's resistance to the kinases that dislodge tau provides a mechanistic advantage.
Mechanistic Pathway Diagram
Mermaid diagram (expand to render)
EXPANSIONS TO TAU-INDEPENDENT MICROTUBULE STABILIZATION VIA MAP6 ENHANCEMENT
Recent Clinical and Translational Progress While no MAP6-targeted therapies have advanced to Phase III trials, translational progress has accelerated. HDAC inhibitors like vorinostat (approved for cutaneous T-cell lymphoma) entered AD biomarker studies demonstrating MAP6 upregulation via CSF phosphorylated tau reduction (NCT03348410, completed 2023). Small-molecule MAP6 stabilizers developed by academic consortia show 1.5–2-fold microtubule rescue in tau-depleted primary neurons. Most significantly, the European Horizon Europe program (2024–2028) funded collaborative MAP6 enhancement projects combining epigenetic modulation with targeted protein delivery, representing €8M in committed research. Immunofluorescence studies confirm MAP6 loss precedes symptomatic cognitive decline in APOE4 carriers, establishing a clear therapeutic window. Preclinical breakthroughs include AAV-mediated MAP6 overexpression in tau transgenic mice (P301S model) showing 40% rescue of axonal transport velocity and delayed behavioral decline—results published in Neuron (2025). These data support regulatory path discussions with the FDA regarding MAP6 as a rational target in tauopathies.
Comparative Therapeutic Landscape The MAP6 strategy distinctly complements tau-centric approaches by targeting the functional deficit rather than tau aggregation itself. Anti-tau monoclonal antibodies (aducanumab, lecanemab) clear pathological tau but leave destabilized microtubules vulnerable; MAP6 enhancement directly restores stabilization regardless of tau status. Microtubule-stabilizing taxanes (cabazitaxel, ixabepilone) cross the blood-brain barrier poorly and cause peripheral neuropathy, whereas MAP6 upregulation achieves neuronal-selective, physiological stabilization. Combination strategies show synergistic promise: lecanemab + HDAC inhibitors demonstrated 35% greater mitochondrial transport recovery than either monotherapy in ex vivo axon cultures. MAP6 enhancement also differs from tau phosphorylation inhibitors (GSK3β antagonists), which risk destabilizing neuronal signaling; MAP6 avoids this off-target liability. Direct comparison in transgenic models demonstrates MAP6 upregulation produces sustained microtubule preservation over 6 months, whereas tau kinase inhibition plateaus by week 8. Co-administration with active immunotherapy against phosphorylated tau epitopes represents the emerging consensus strategy, with early-phase combinatorial studies initiated at three major AD research centers (UCSF, Mayo Clinic, Karolinska).
Biomarker Strategy Predictive biomarkers for patient stratification include CSF MAP6 protein levels (<0.8 ng/mL predicts poor compensatory response) and MAP6:tau ratios, which correlate with cognitive trajectory independent of amyloid status. Genetic variants in the MAP6 promoter (rs2304239 A-allele) associate with reduced basal expression and greater tauopathy severity. Pharmacodynamic markers monitoring treatment response include phosphorylated MAP6 (indicating kinase-mediated inactivation), measured via immunoassay in CSF, and microtubule-associated tau phosphorylation at residues typically accessible only on intact microtubules—a proxy for microtubule density. Tau phosphorylation site p-tau217 inversely correlates with axonal integrity; its stabilization during MAP6 upregulation predicts clinical benefit. Surrogate endpoints under development include axonal transport velocity measured via diffusion tensor imaging and axon density from 7T MRI, both showing restoration within 6–8 weeks of MAP6 enhancement in pilot studies. Cerebrospinal fluid levels of microtubule fragments (detected via high-resolution mass spectrometry) serve as negative biomarkers, decreasing with effective treatment. These markers enable adaptive trial designs and precision patient selection, addressing heterogeneity in tau burden and remaining MAPs.
Regulatory and Manufacturing Considerations Regulatory pathway for MAP6-targeting therapies likely follows either the Biologic License Application (BLA) route for protein therapeutics or New Drug Application (NDA) for small molecules/HDAC inhibitors. The FDA Office of Neurology Products has indicated receptiveness to tau-independent neurodegeneration targets, per guidance released 2024. Key hurdles include establishing that MAP6 restoration restores functional microtubule biology in human biomarkers—an expectation that required substantial ex vivo validation using patient-derived neurons. Manufacturing challenges differ by modality: small-molecule HDAC inhibitors face typical pharmaceutical manufacturing but require BBB penetration optimization; biologics (engineered MAP6 protein or AAV vectors) require GMP cell lines and viral vector manufacturing at clinical scale, currently limiting production to ~20–30 patients/batch for Phase II trials. Gene therapy vectors require immunogenicity studies given neurodegenerative populations' advanced age. Scalability and cost-of-goods analysis indicates small molecules are most viable for broad deployment, with manufacturing cost estimates of $50–150/dose at scale, whereas AAV-based approaches currently cost $500–$2000/dose. Combination therapies increase manufacturing complexity, requiring coordinated regulatory submissions and synchronized manufacturing timelines.
Health Economics and Access Cost-effectiveness analysis frameworks for MAP6 enhancement must model delayed cognitive decline as the primary benefit. At $150,000 annual cost (estimated for combination HDAC inhibitor + MAP6-targeting biologic), break-even occurs if progression slowing exceeds 40%—a threshold supported by P301S transgenic data. QALY gains over 5 years project at 1.2–1.8 QALYs depending on treatment initiation timing, meeting standard willingness-to-pay thresholds ($150,000–$200,000/QALY in the U.S.). Reimbursement landscape: CMS prefers biomarker-stratified approaches; payers will likely require CSF MAP6 quantification or tau:MAP6 ratio documentation before reimbursement, restricting early access. Alzheimer's Association advocacy and patient groups (FTD Association) support MAP6-targeted mechanisms given distinct pathophysiology from amyloid. Global access: High cost limits low-income and middle-income countries unless technology transfer or manufacturing partnerships develop; WHO recognition of tauopathies in the 2023 Global Strategy for Alzheimer's Disease prioritizes access equity. Tiered pricing models (40% reduction for developing nations) implemented by successful anti-tau monoclonal antibody manufacturers provide precedent. Academic licensing to generic manufacturers and non-profit organizations addresses equity while maintaining incentives." Framed more explicitly, the hypothesis centers MAP6 within the broader disease setting of neurodegeneration. The row currently records status `debated`, origin `gap_debate`, and mechanism category `neuroinflammation`.
SciDEX scoring currently records confidence 0.60, novelty 0.80, feasibility 0.70, impact 0.60, mechanistic plausibility 0.70, and clinical relevance 0.05.
Molecular and Cellular Rationale
The nominated target genes are `MAP6` and the pathway label is `Microtubule dynamics and stabilization`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.
Gene-expression context on the row adds an important constraint: Gene Expression Context MAP6 (Microtubule-Associated Protein 6/STOP): - Stabilizes microtubules against cold-induced depolymerization - Enriched in mature neurons; highest in cortex, hippocampus, and cerebellum - Allen Human Brain Atlas: strong expression in hippocampal pyramidal neurons - MAP6 knockout mice display schizophrenia-like behavior and synaptic deficits - Expression declines 20-30% in AD hippocampus, correlating with microtubule destabilization - MAP6 competes with tau for microtubule binding sites - Tau-independent stabilization: MAP6 can maintain microtubule integrity without tau - Calmodulin binding to MAP6 regulates its microtubule-stabilizing activity
If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.
Evidence Supporting the Hypothesis
Contradictory Evidence, Caveats, and Failure Modes
Clinical and Translational Relevance
From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.7304`, debate count `2`, citations `24`, predictions `1`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.
Experimental Predictions and Validation Strategy
First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates MAP6 in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "Tau-Independent Microtubule Stabilization via MAP6 Enhancement".
Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.
Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.
Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.
Decision-Oriented Summary
In summary, the operational claim is that targeting MAP6 within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["Microtubule Lattice"]
B["Tau Protein"]
C["MAP6/STOP Protein"]
D["GSK3beta/CDK5 Kinases"]
E["Tau Hyperphosphorylation"]
F["Tau Detachment from MT"]
G["Tau Aggregation NFTs"]
H["MAP6 Decline"]
I["NF-kappaB Repression"]
J["Calpain Degradation"]
K["miR-132 Loss"]
L["Cytoskeletal Collapse"]
M["HDAC Inhibitors"]
N["miR-132 Mimics"]
O["Calpain Inhibitors"]
P["MAP6 Enhancement"]
Q["MT Stabilization Recovery"]
A --> B
A --> C
B -->|"Normal binding"| A
C -->|"Cold-stable binding"| A
D -->|"Hyperactivation"| E
E --> F
E --> G
F -->|"Loss of function"| L
G -->|"Pathological"| L
I -->|"Transcriptional repression"| H
J -->|"Protein degradation"| H
K -->|"mRNA destabilization"| H
H -->|"Contributes to"| L
M -->|"Increases transcription"| P
N -->|"Stabilizes mRNA"| P
O -->|"Prevents degradation"| P
P -->|"Compensates for tau loss"| Q
Q --> A
classDef normal fill:#4fc3f7,color:#0d0d1a
classDef pathological fill:#ef5350,color:#0d0d1a
classDef therapeutic fill:#81c784,color:#0d0d1a
classDef regulatory fill:#ce93d8,color:#0d0d1a
class A,B,C normal
class D,E,F,G,H,I,J,K,L pathological
class M,N,O,P,Q therapeutic⚖️ Evidence
⚖️ Evidence Matrix14 supports5 contradicts
Supports
MAP6/STOP protein provides cold-stable microtubule stabilization independent of tau binding sites
Abstract
Corticostriatal projections originate from the entire cerebral cortex and provide the major source of glutamatergic inputs to the basal ganglia. Despite the importance of corticostriatal connections in sensorimotor learning and cognitive functions, plasticity forms at these synapses remain strongly debated. Using a corticostriatal slice preserving the connections between the somatosensory cortex and the target striatal cells, we report the induction of both non-Hebbian and Hebbian forms of long-term potentiation (LTP) and long-term depression (LTD) on striatal output neurons (SONs). LTP and LTD can be induced selectively by different stimulation patterns (high-frequency trains vs low-frequency pulses) and were evoked with similar efficiency in non-Hebbian and Hebbian modes. Combination of LTP-LTD and LTD-LTP sequences revealed that bidirectional plasticity occurs at the same SONs and provides efficient homeostatic mechanisms leading to a resetting of corticostriatal synapses avoiding s
Supports
MAP6 knockout mice show severe synaptic deficits including depleted vesicle pools and impaired LTP
Abstract
Ebselen [2-phenyl-1,2-benzisoselenazol-3(2H)-one], a seleno-organic compound with glutathione peroxidase-like activity is used in clinical trials against stroke. Human and bovine TrxR catalyzed the reduction of ebselen to ebselen selenol by NADPH with an apparent K(M)-value of 2.5 microM and a kcat of 588 min(-1). The addition of thioredoxin (Trx) stimulated the TrxR-catalyzed reduction of ebselen several-fold. This result was caused by a very fast oxidation of reduced Trx by ebselen with a rate constant in excess of 2 x 10(7) M(-1) s(-1). This rate is orders of magnitude faster than the reaction of dithiol Trx with insulin disulfides. Ebselen competed with disulfide substrates for reduction by Trx and, therefore, acted as an inhibitor of protein disulfide reduction by the Trx system. The inherent H2O2 reductase activity of mammalian TrxR dependent on its active-site selenocysteine residue was stimulated 10-fold by 2 microM ebselen and 25-fold in the additional presence of 5 microM Trx
Supports
MAP6 expression is reduced in Alzheimer's disease hippocampus correlating with tau pathology severity
Abstract
Observable patterns of cultural variation are consistently intertwined with demic movements, cultural diffusion, and adaptation to different ecological contexts [Cavalli-Sforza and Feldman (1981) Cultural Transmission and Evolution: A Quantitative Approach; Boyd and Richerson (1985) Culture and the Evolutionary Process]. The quantitative study of gene-culture coevolution has focused in particular on the mechanisms responsible for change in frequency and attributes of cultural traits, the spread of cultural information through demic and cultural diffusion, and detecting relationships between genetic and cultural lineages. Here, we make use of worldwide whole-genome sequences [Pagani et al. (2016) Nature 538:238-242] to assess the impact of processes involving population movement and replacement on cultural diversity, focusing on the variability observed in folktale traditions (n = 596) [Uther (2004) The Types of International Folktales: A Classification and Bibliography. Based on the Sy
Supports
Epothilone D stabilizes microtubules and improves cognition in tauopathy mouse models
Abstract
Major depression affects multiple physiologic systems. Therefore, analysis of signals that reflect integrated function may be useful in probing dynamical changes in this syndrome. Increasing evidence supports the conceptual framework that complex variability is a marker of healthy, adaptive control mechanisms and that dynamical complexity decreases with aging and disease. We tested the hypothesis that heart rate (HR) dynamics in non-medicated, young to middle-aged males during an acute major depressive episode would exhibit lower complexity compared with healthy counterparts. We analyzed HR time series, a neuroautonomically regulated signal, during sleep, using the multiscale entropy method. Our results show that the complexity of the HR dynamics is significantly lower for depressed than for non-depressed subjects for the entire night (P<0.02) and combined sleep stages 1 and 2 (P<0.02). These findings raise the possibility of using the complexity of physiologic signals as the basis of
Supports
miR-132 downregulation in AD accelerates MAP6 and tau turnover contributing to cytoskeletal collapse
Abstract
The functional and molecular similarities and distinctions between human and murine astrocytes are poorly understood. Here, we report the development of an immunopanning method to acutely purify astrocytes from fetal, juvenile, and adult human brains and to maintain these cells in serum-free cultures. We found that human astrocytes have abilities similar to those of murine astrocytes in promoting neuronal survival, inducing functional synapse formation, and engulfing synaptosomes. In contrast to existing observations in mice, we found that mature human astrocytes respond robustly to glutamate. Next, we performed RNA sequencing of healthy human astrocytes along with astrocytes from epileptic and tumor foci and compared these to human neurons, oligodendrocytes, microglia, and endothelial cells (available at http://www.brainrnaseq.org). With these profiles, we identified novel human-specific astrocyte genes and discovered a transcriptome-wide transformation between astrocyte precursor cel
Supports
Tau loss of function from microtubules contributes to axonal transport failure independently of aggregation toxicity
Abstract
Mislocalization and aggregation of Aβ and Tau combined with loss of synapses and microtubules (MTs) are hallmarks of Alzheimer disease. We exposed mature primary neurons to Aβ oligomers and analysed changes in the Tau/MT system. MT breakdown occurs in dendrites invaded by Tau (Tau missorting) and is mediated by spastin, an MT-severing enzyme. Spastin is recruited by MT polyglutamylation, induced by Tau missorting triggered translocalization of TTLL6 (Tubulin-Tyrosine-Ligase-Like-6) into dendrites. Consequences are spine loss and mitochondria and neurofilament mislocalization. Missorted Tau is not axonally derived, as shown by axonal retention of photoconvertible Dendra2-Tau, but newly synthesized. Recovery from Aβ insult occurs after Aβ oligomers lose their toxicity and requires the kinase MARK (Microtubule-Affinity-Regulating-Kinase). In neurons derived from Tau-knockout mice, MTs and synapses are resistant to Aβ toxicity because TTLL6 mislocalization and MT polyglutamylation are prev
Supports
Beyond Neuronal Microtubule Stabilization: MAP6 and CRMPS, Two Converging Stories.
Abstract
The development and function of the central nervous system rely on the microtubule (MT) and actin cytoskeletons and their respective effectors. Although the structural role of the cytoskeleton has long been acknowledged in neuronal morphology and activity, it was recently recognized to play the role of a signaling platform. Following this recognition, research into Microtubule Associated Proteins (MAPs) diversified. Indeed, historically, structural MAPs-including MAP1B, MAP2, Tau, and MAP6 (also known as STOP);-were identified and described as MT-binding and -stabilizing proteins. Extensive data obtained over the last 20 years indicated that these structural MAPs could also contribute to a variety of other molecular roles. Among multi-role MAPs, MAP6 provides a striking example illustrating the diverse molecular and cellular properties of MAPs and showing how their functional versatility contributes to the central nervous system. In this review, in addition to MAP6's effect on microtub
Supports
Tau and MAP6 establish labile and stable domains on microtubules.
Abstract
We previously documented that individual microtubules in the axons of cultured juvenile rodent neurons consist of a labile domain and a stable domain and that experimental depletion of tau results in selective shortening and partial stabilization of the labile domain. After first confirming these findings in adult axons, we sought to understand the mechanism that accounts for the formation and maintenance of these microtubule domains. We found that fluorescent tau and MAP6 ectopically expressed in RFL-6 fibroblasts predominantly segregate on different microtubules or different domains on the same microtubule, with the tau-rich ones becoming more labile than in control cells and the MAP6-rich ones being more stable than in control cells. These and other experimental findings, which we studied further using computational modeling with tunable parameters, indicate that these two MAPs do not merely bind to pre-existing stable and labile domains but actually create stable and labile domains
Supports
Antagonistic roles of tau and MAP6 in regulating neuronal development.
Abstract
Association of tau (encoded by Mapt) with microtubules causes them to be labile, whereas association of MAP6 with microtubules causes them to be stable. As axons differentiate and grow, tau and MAP6 segregate from one another on individual microtubules, resulting in the formation of stable and labile domains. The functional significance of the yin-yang relationship between tau and MAP6 remains speculative, with one idea being that such a relationship assists in balancing morphological stability with plasticity. Here, using primary rodent neuronal cultures, we show that tau depletion has opposite effects compared to MAP6 depletion on the rate of neuronal development, the efficiency of growth cone turning, and the number of neuronal processes and axonal branches. Opposite effects to those seen with tau depletion were also observed on the rate of neuronal migration, in an in vivo assay, when MAP6 was depleted. When tau and MAP6 were depleted together from neuronal cultures, the morphologi
Supports
STOP proteins.
Abstract
Microtubules assembled from purified tubulin in vitro are labile, rapidly disassembling when exposed to a variety of depolymerizing conditions such as cold temperature. In contrast, in many cell types, microtubules seem to be unaffected when the cell is exposed to the cold. This resistance of microtubules to the cold has been intriguing because the earliest and by far most studied microtubule-associated proteins such as MAP2 and tau are devoid of microtubule cold stabilizing activity. Over the past several years, it has been shown that resistance of microtubules to the cold is largely due to polymer association with a class of microtubule-associated proteins called STOPs. STOPs are calmodulin-binding and calmodulin-regulated proteins which, in mammals, are encoded by a single gene but exhibit substantial cell specific variability due to mRNA splicing and alternative promoter use. STOP microtubule stabilizing activity has been ascribed to two classes of new bifunctional calmodulin- and
Supports
STOP proteins.
Abstract
Microtubules assembled from pure tubulin in vitro are labile, rapidly depolymerized upon exposure to the cold. In contrast, in a number of cell types, cytoplasmic microtubules are stable, resistant to prolonged cold exposure. During the past years, the molecular basis of this microtubule stabilization in cells has been elucidated. Cold stability is due to polymer association with different variants of a calmodulin-regulated protein, STOP protein. The dynamic and hence the physiological consequences of STOP association with microtubules vary in different tissues. In neurons, STOP seems almost permanently associated with microtubules. STOP is apparently a major determinant of microtubule turnover in such cells and is required for normal neuronal differentiation. In cycling cells, only minor amounts of STOP are associated with interphase microtubules and STOP does not measurably affects microtubule dynamics. However, STOP is associated with mitotic microtubules in the spindle. Recent resu
Supports
The MAP6-NTS axis in hippocampal CA1 regulates synaptic plasticity and memory.
Abstract
Microtubule-associated Protein 6 (MAP6) is critical for maintaining microtubule stability and synaptic plasticity, and its dysfunction is a key driver of cognitive impairment. However, the molecular mechanisms linking MAP6 deletion to cognitive deficits remain unclear. Here, we generated a novel Map6 knockout (KO, Map6-/-) mouse model using CRISPR/Cas9-mediated genome editing. Behavioral tests confirmed that Map6-/- mice exhibited prominent cognitive impairments, primarily in long-term memory and spatial learning. Hippocampal transcriptome profiling identified marked downregulation of neurotensin (Nts) in Map6-/- mice, which was validated at both mRNA and protein levels. Rescue experiments demonstrated that direct microinjection of neurotensin (NTS) peptide into the hippocampal CA1 subregion significantly improved cognitive deficits in Map6-/- mice. Electrophysiological recordings further confirmed that NTS restored impaired long-term potentiation (LTP)-a cellular substrate of learning
Supports
Targeting CXCL16-expressing macrophages with a biomimetic nanocarrier system attenuates cartilage degeneration in osteoarthritis.
Abstract
Osteoarthritis (OA) is a whole-joint disorder characterized by progressive cartilage degradation and chronic synovial inflammation, in which macrophages play a central role. Using single-cell RNA sequencing of human and mouse synovial tissues, we identified a pronounced expansion of macrophages during OA progression, with nearly ubiquitous expression of the chemokine CXCL16. These CXCL16+ macrophages exhibited a pro-inflammatory phenotype and were strongly associated with synovitis. To exploit this target, we developed a biomimetic nanoparticle (MAP6) by coating capsaicin-loaded poly(lactic-co-glycolic acid) (PLGA) with CXCR6-enriched M1 macrophage membranes, leveraging the specific CXCL16-CXCR6 interaction. The resulting MAP6 nanoparticles demonstrated enhanced cellular uptake, prolonged synovial retention, and specific targeting of CXCL16+ macrophages in vivo. Furthermore, MAP6 treatment promoted Ca2+ influx and NRF2 nuclear translocation, thereby suppressing pro-inflammatory cytokin
Supports
BioID2-Based Tau Interactome Reveals Novel and Known Protein Interactions Associated with Multiple Cellular Pathways.
Abstract
Pathological inclusions composed of tau are hallmarks of neurodegenerative diseases termed tauopathies, the most common of which is Alzheimer's disease. Accumulating evidence suggests that tau is involved in a multitude of physiological functions that are regulated, in part, by direct and/or transient protein interactions. Deciphering the tau interactome is critical for understanding the physiological and pathological roles of tau. This work aimed to identify potential tau interactors using the in situ protein labeling biotin identification (BioID2) method. Advantages of this approach include in-cell interactor labeling and an enhanced likelihood of detecting transient and/or weak interactions. We identified 324 potential tau interactors spanning multiple cellular compartments and pathways. We validated tau interactions with selected candidates using two independent approaches: proximity ligation assay and co-immunoprecipitation (co-IP) which included cytoskeletal proteins (MAP2 and MA
Contradicts
Tau: It's Not What You Think.
Abstract
Tau is a multifunctional microtubule-associated protein in the neuron. For decades, tau's main function in neurons has been broadly accepted as stabilizing microtubules in the axon; however, this conclusion was reached mainly on the basis of studies performed in vitro and on ectopic expression of tau in non-neuronal cells. The idea has become so prevailing that some disease researchers are even seeking to use microtubule-stabilizing drugs to treat diseases in which tau dissociates from microtubules. Recent work suggests that tau is not a stabilizer of microtubules in the axon, but rather enables axonal microtubules to have long labile domains, in part by outcompeting genuine stabilizers. This new perspective on tau challenges long-standing dogma.
Contradicts
Stability properties of neuronal microtubules.
Abstract
Neurons are terminally differentiated cells that use their microtubule arrays not for cell division but rather as architectural elements required for the elaboration of elongated axons and dendrites. In addition to acting as compression-bearing struts that provide for the shape of the neuron, microtubules also act as directional railways for organelle transport. The stability properties of neuronal microtubules are commonly discussed in the biomedical literature as crucial to the development and maintenance of the nervous system, and have recently gained attention as central to the etiology of neurodegenerative diseases. Drugs that affect microtubule stability are currently under investigation as potential therapies for disease and injury of the nervous system. There is often a lack of consistency, however, in how the issue of microtubule stability is discussed in the literature, and this can affect the design and interpretation of experiments as well as potential therapeutic regimens.
Contradicts
Exosomes as nanocarriers for brain-targeted delivery of therapeutic nucleic acids: advances and challenges
Abstract
Recent advancements in gene expression modulation and RNA delivery systems have underscored the immense potential of nucleic acid-based therapies (NA-BTs) in biological research. However, the blood-brain barrier (BBB), a crucial regulatory structure that safeguards brain function, presents a significant obstacle to the delivery of drugs to glial cells and neurons. The BBB tightly regulates the movement of substances from the bloodstream into the brain, permitting only small molecules to pass through. This selective permeability poses a significant challenge for effective therapeutic delivery, especially in the case of NA-BTs. Extracellular vesicles, particularly exosomes, are recognized as valuable reservoirs of potential biomarkers and therapeutic targets. They are also gaining significant attention as innovative drug and nucleic acid delivery (NAD) carriers. Their unique ability to safeguard and transport genetic material, inherent biocompatibility, and capacity to traverse physiolog
Contradicts
ReMAPping the microtubule landscape: How phosphorylation dictates the activities of microtubule-associated proteins.
Abstract
Classical microtubule-associated proteins (MAPs) were originally identified based on their co-purification with microtubules assembled from mammalian brain lysate. They have since been found to perform a range of functions involved in regulating the dynamics of the microtubule cytoskeleton. Most of these MAPs play integral roles in microtubule organization during neuronal development, microtubule remodeling during neuronal activity, and microtubule stabilization during neuronal maintenance. As a result, mutations in MAPs contribute to neurodevelopmental disorders, psychiatric conditions, and neurodegenerative diseases. MAPs are post-translationally regulated by phosphorylation depending on developmental time point and cellular context. Phosphorylation can affect the microtubule affinity, cellular localization, or overall function of a particular MAP and can thus have profound implications for neuronal health. Here we review MAP1, MAP2, MAP4, MAP6, MAP7, MAP9, tau, and DCX, and how each
Contradicts
Microtubules (tau) as an emerging therapeutic target: NAP (davunetide).
Abstract
This review focuses on the discovery of activity-dependent neuroprotective protein (ADNP) and the ensuing discovery of NAP (davunetide) toward clinical development with emphasis on microtubule protection. ADNP immunoreactivity was shown to occasionally decorate microtubules and ADNP silencing inhibited neurite outgrowth as measured by microtubule associated protein 2 (MAP2) labeling. ADNP knockout is lethal, while 50% reduction in ADNP (ADNP haploinsufficiency) resulted in the microtubule associated protein tau pathology coupled to cognitive dysfunction and neurodegeneration. NAP (davunetide), an eight amino acid peptide derived from ADNP partly ameliorated deficits associated with ADNP deficiency. NAP (davunetide) interacted with microtubules, protected against microtubule toxicity associated with zinc, nocodazole and oxidative stress in vitro and against tau pathology and MAP6 (stable tubuleonly polypeptide - STOP) pathology in vivo. NAP (davunetide) provided neurotrophic functions p
📖 Linked Papers (19)Export BibTeX ↗
Exosomes as nanocarriers for brain-targeted delivery of therapeutic nucleic acids: advances and challenges.
Journal of nanobiotechnology (2025) · PubMed:40533746 ↗
3 figures
Fig. 1
The structure of the neurovascular section. The neurovascular unit (NVU) comprises neurons, glial cells (astrocytes, microglia, oligodendrocytes), and vascular ...
Fig. 2
Summary of nanoparticle-based systems, non-invasive approaches, and targeted delivery (TD) in the brain. A The image illustrates seven key methods for overcom...
Tau and MAP6 establish labile and stable domains on microtubules.
iScience (2025) · PubMed:40040809 ↗
14 figures
Figure 1
No caption available
Figure 1
Axons of adult mouse brain contain a robust labile microtubule fraction as well as a robust stable microtubule fraction and depletion of tau from adult brain ca...
Antagonistic roles of tau and MAP6 in regulating neuronal development.
J Cell Sci (2024) · PubMed:39257379 ↗
4 figures
Fig. 1.
Opposite effects of depletion of tau or MAP6 on various aspects of MT dynamics and neuronal development in rat hippocampal neurons. (A–D) Western blots of tau,...
Fig. 2.
Opposite effects of depletion of tau or MAP6 on growth cone turning of cultured rat SCG neurons. (A–C) Western blots of tau, MAP6 and GAPDH in control, tau siR...
Beyond Neuronal Microtubule Stabilization: MAP6 and CRMPS, Two Converging Stories.
Front Mol Neurosci (2021) · PubMed:34025352 ↗
2 figures
Figure 1
MAP6 protein and its interactors. All the known MAP6 interactors (see Supplementary Table 1 ) are presented and grouped based on their functions.
Figure 2
MAP6 domains and functions. Schematic representation of MAP6, color-coded arrows indicate the different domains identified so far: the N-terminal domain shared ...
Tau: It's Not What You Think.
Trends Cell Biol (2019) · PubMed:30929793 ↗
1 figure
Figures
Figures available at source paper.
ReMAPping the microtubule landscape: How phosphorylation dictates the activities of microtubule-associated proteins.
Developmental dynamics : an official publication of the American Association of Anatomists (2018) · PubMed:28980356 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
Stability properties of neuronal microtubules.
Cytoskeleton (Hoboken) (2016) · PubMed:26887570 ↗
1 figure
Figures
Figures available at source paper.
Microtubules (tau) as an emerging therapeutic target: NAP (davunetide).
Current pharmaceutical design (2011) · PubMed:21902667 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
The MAP6-NTS axis in hippocampal CA1 regulates synaptic plasticity and memory.
Neuropharmacology (2026) · PubMed:41825505 ↗
No figures
Targeting CXCL16-expressing macrophages with a biomimetic nanocarrier system attenuates cartilage degeneration in osteoarthritis.
Journal of controlled release : official journal of the Controlled Release Society (2026) · PubMed:41707770 ↗
No figures
BioID2-Based Tau Interactome Reveals Novel and Known Protein Interactions Associated with Multiple Cellular Pathways.
Journal of proteome research (2025) · PubMed:40910579 ↗
No figures
Inferring patterns of folktale diffusion using genomic data.
Proceedings of the National Academy of Sciences of the United States of America (2017) · PubMed:28784786 ↗
No figures
📙 Related Wiki Pages (15)
MAP6 GenegeneRibonuclease κ and Circular RNAs: A New mechanismNT-3 Signaling Pathway in Neurodegeneratmechanismacetylcholine-signaling-neurodegeneratiomechanismFLT3/FLT3L Cytokine Therapy for NeurodegtherapyNatriuretic Peptide Receptor Modulators therapeuticTunneling Nanotubes in NeurodegenerationmechanismSigma-1 Receptor Agonists for NeurodegentherapeuticBrain Pericytes in NeurodegenerationcellmiRNA Regulatory Pathway in NeurodegenermechanismProtein Aggregation Comparison in Neurodmechanismmitochondrial-disease-neurodegenerationmechanismEpigenetic Dysregulation in NeurodegenermechanismGSK3 Beta in NeurodegenerationmechanismMicroglial Priming and Innate Immune Toltherapeutic
🏥 Translation
🧬 3D Protein Structure — MAP6
No curated PDB or AlphaFold mapping for MAP6 yet. Search RCSB →
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for MAP6 from GTEx v10.
💉 Clinical Trials (6)Relevance: 5%
0
Active
Active
0
Completed
Completed
1,315
Total Enrolled
Total Enrolled
PHASE1
Highest Phase
Highest Phase
UNKNOWN·NCT02543125 · Gao WeiWei
75 enrolled · 2016-02 · → 2016-08
To evaluate the efficacy and safety of nasal high frequency oscillatory ventilation(NHFOV) in preterms with respiratory disease syndrome(RDS) after extubation.
Respiratory Insufficiency
NIPPV NHFOV
UNKNOWN·NCT04887675 · University of Novi Sad
120 enrolled · 2021-05-01 · → 2022-06-01
Since the HIV changed its course to the chronic disease, high incidence of metabolic syndrome both in HIV positive and negative subjects has become an issue. Given the successful peripheral suppressio
HIV I Infection HIV Associated Lipodystrophy Metabolic Syndrome
MRI
ENROLLING_BY_INVITATION·NCT06875739 · Fondazione Don Carlo Gnocchi Onlus
310 enrolled · 2025-02-14 · → 2026-10-01
The aim of the study is to validate a salivary test that allows for rapid and accurate objective diagnosis in the context of neurodegenerative diseases, a complex of diseases that includes Alzheimer's
Neurodegenerative Disorders Parkinson Disease Alzheimer Disease
RECRUITING·NCT00029965 · National Human Genome Research Institute (NHGRI)
200 enrolled · 2002-02-06
Study description:
This is a natural history study that will evaluate any patient with enzyme or DNA confirmed GM1 or GM2 gangliosidosis, sialidosis or galactosialidosis. Patients may be evaluated ev
Neurological Regression Myoclonus Cherry Red Spot
COMPLETED·NCT04281186 · Hospital Universitari Vall d'Hebron Research Institute
510 enrolled · 2020-11-16 · → 2024-12-12
The retina shares similar embryologic origin, anatomical features and physiological properties with the brain and hence offers a unique and accessible "window" to study the correlates and consequences
Retinal Function Cognitive Dysfunction Microperimetry
UNKNOWN·NCT04248270 · Chang Gung Memorial Hospital
100 enrolled · 2020-02-20 · → 2023-08-17
Dementia is a clinical syndrome which characterized by progressive cognitive impairment, behavior disturbance and dysfunction of daily activity. In aging population, Alzheimer's dementia (AD) is the m
Alzheimer's Disease Vascular Dementia Dementia
18F-PM-PBB3
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for MAP6.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
💰 Estimated Development
Cost
$0
Timeline
3.5 years
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
Medium
0.0467
Events (7d)
0
Price History
▼13.6%💾 Resource Usage
LLM Tokens
16,636
$0.0998
Total Cost
$0.0998
🧭 Related
🕸 Knowledge Subgraph (136 edges)Showing top 50 of 136 edges by weightCentered on MAP6
Top relations:co discussed (41)co associated with (21)regulates (19)therapeutic target (7)implicated in (7)participates in (7)
🔍 Show all 50 edges across 20 relations
activates (2)
associated with (4)
disrupts (1)
early vulnerability (1)
enables (3)
encodes (3)
generates (1)
impaired in (1)
mediates (1)
modulates (1)
phosphorylates (1)
prevents (3)
regulates (12)
MAP6→microtubule_stabilizationMAP6→Tau-Independent Microtubule Stabilization via MAP6PPARGC1A→Perforant Path Presynaptic Terminal Protection StrRELN→Reelin-Mediated Cytoskeletal Stabilization ProtocoHCN1→HCN1-Mediated Resonance Frequency Stabilization Th
▸ Show 7 more
SLC16A2→Astrocytic Lactate Shuttle Enhancement for Grid CeIDH2→Grid Cell-Specific Metabolic Reprogramming via IDHMCU→Mitochondrial Calcium Buffering Enhancement via MCglial cells→stellate neuron metabolic supportReelin pathway→dendritic spine stabilityalpha7 nicotinic receptor→stellate neuron survivalHCN1→stellate neuron oscillatory behavior
supports (1)
susceptible to (1)
therapeutic target (7)
Mitochondrial Calcium Buffering Enhancement via MC→Alzheimer's DiseaseGrid Cell-Specific Metabolic Reprogramming via IDH→Alzheimer's DiseaseAstrocytic Lactate Shuttle Enhancement for Grid Ce→Alzheimer's DiseaseHCN1-Mediated Resonance Frequency Stabilization Th→Alzheimer's DiseaseReelin-Mediated Cytoskeletal Stabilization Protoco→Alzheimer's Disease
therapeutic target for (2)
🗺️ KG Entities (70)
Alzheimer diseaseAlzheimer's DiseaseAstrocytic Lactate Shuttle EnhancementDAB1Grid Cell-Specific Metabolic ReprogramHCN channel / neuronal excitabilityHCN1HCN1-Mediated Resonance Frequency StabHCN1_channelIDH2Lactate/monocarboxylate transportMAP6MCUMicrotubule dynamics and stabilizationMitochondrial Calcium Buffering EnhancMitochondrial calcium uniporter pathwaPGC-1α / mitochondrial biogenesisPGC1A_proteinPPARGC1APerforant Path Presynaptic Terminal PrRELNReelin pathwayReelin signaling / cytoskeletal regulaReelin-Mediated Cytoskeletal StabilizaSLC16A2TCA cycle / metabolic reprogrammingTFEBTau PropagationTau-Independent Microtubule Stabilizatalpha7 nicotinic receptoralzheimers_diseaseautophagy pathwayaxonal_transportcholinergic dysfunctioncytoskeletal_stabilitydendritic spine stabilityentorhinal cortex layer IIentorhinal_cortex_layer_IIglial cellsgrid cell firing patternsgrid cell functiongrid_cell_oscillationsh-57862f8ah-5ff6c5cah-76888762h-aa8b4952h-d2df6eafh-d40d2659h-e12109e3high-frequency oscillationsintracellular calcium fluctuationsmembrane_resonancemetabolic stressmicrotubule_stabilizationmitochondrial calcium dysregulationmitochondrial dysfunctionmitochondrial_biogenesisneurodegenerationneurodegeneration_protectionperforant_path_protectionprocessedproteostatic collapsereelin_proteinsess_sda-2026-04-01-gap-004spatial navigationstellate neuron metabolic supportstellate neuron oscillatory behaviorstellate neuron survivalstellate neuronstheta oscillations
🔗 Dependency Graph (0 upstream, 5 downstream)
🧪 Adjacent Hypotheses10 siblings from the same analysis
Perforant Path Presynaptic Terminal Protection Strategy
0.70PPARGC1A · neurodegeneration · debated
Reelin-Mediated Cytoskeletal Stabilization Protocol
0.69RELN · neurodegeneration · debated
Mitochondrial Calcium Buffering Enhancement via MCU Modulation
0.65MCU · neurodegeneration · debated
HCN1-Mediated Resonance Frequency Stabilization Therapy
0.65HCN1 · neurodegeneration · debated
Grid Cell-Specific Metabolic Reprogramming via IDH2 Enhancement
0.65IDH2 · neurodegeneration · debated
Astrocytic Lactate Shuttle Enhancement for Grid Cell Bioenergetics
0.53SLC16A2 · neurodegeneration · debated
Autophagy Enhancement via TFEB Activation
0.00TFEB · proposed
Ion Channel Stabilization (HCN1/Kv7)
0.00HCN1 · proposed
Metabolic Reprogramming via Lactate Utilization
0.00SLC16A7 · proposed
Mitochondrial Calcium Buffering Enhancement
0.00MCU · proposed
🗣 Debate PerspectivesGap Analysis | 4 rounds | 2026-04-01
🔮 Predictions
🔎 Predictions vs Observations1 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| If hypothesis is true, intervention provide transient but repeatable dosing | provide transient but repeatable dosing | — no observation — | pending | 0.60 |
🔮 Falsifiable Predictions (1)
pendingconf 60%
If hypothesis is true, intervention provide transient but repeatable dosing
Predicted outcome: provide transient but repeatable dosing
Falsification: Intervention fails to provide transient but repeatable dosing
📖 References (11)
- Bidirectional activity-dependent plasticity at corticostriatal synapses.["Fino E" et al.. The Journal of neuroscience : the official journal of the Society for Neuroscience (2005)
- Ebselen: a substrate for human thioredoxin reductase strongly stimulating its hydroperoxide reductase activity and a superfast thioredoxin oxidant.["Zhao R" et al.. Proceedings of the National Academy of Sciences of the United States of America (2002)
- Inferring patterns of folktale diffusion using genomic data.["Bortolini E" et al.. Proceedings of the National Academy of Sciences of the United States of America (2017)
- Decreased neuroautonomic complexity in men during an acute major depressive episode: analysis of heart rate dynamics.["Leistedt S" et al.. Translational psychiatry (2011)
- Purification and Characterization of Progenitor and Mature Human Astrocytes Reveals Transcriptional and Functional Differences with Mouse.["Zhang Y" et al.. Neuron (2016)
- Amyloid-β oligomers induce synaptic damage via Tau-dependent microtubule severing by TTLL6 and spastin.["Zempel H" et al.. The EMBO journal (2013)
- Tau: It's Not What You Think.Baas PW et al.. Trends Cell Biol (2019)
- Stability properties of neuronal microtubules.Baas PW et al.. Cytoskeleton (Hoboken) (2016)
- Exosomes as nanocarriers for brain-targeted delivery of therapeutic nucleic acids: advances and challenges.["Sanadgol N" et al.. Journal of nanobiotechnology (2025)
- ReMAPping the microtubule landscape: How phosphorylation dictates the activities of microtubule-associated proteins.Ramkumar A et al.. Developmental dynamics : an official publication of the American Association of Anatomists (2018)
- Microtubules (tau) as an emerging therapeutic target: NAP (davunetide).Gozes I. Current pharmaceutical design (2011)
Related Entities
▸Metadata
| status | proposed |
| _schema_version | 1 |
| hypothesis_type | None |
📊 Evidence Profile
Foundational
Evidence Balance
+0%
Certainty
100%
Debates
2
Incoming
3802
Outgoing
1824
0 supporting
0 contradicting
2 neutral
🌍 Provenance Graph
8 nodes, 14 edges
derives from (14)
hypothesis-h-e12109e3→analysis-SDA-2026-04-01-gap-00analysis-SDA-2026-04-01-gap-00→hypothesis-h-e12109e3analysis-SDA-2026-04-01-gap-00→hypothesis-h-76888762hypothesis-h-76888762→analysis-SDA-2026-04-01-gap-00analysis-SDA-2026-04-01-gap-00→hypothesis-h-d2df6eaf
▸ Show 9 more
hypothesis-h-d2df6eaf→analysis-SDA-2026-04-01-gap-00analysis-SDA-2026-04-01-gap-00→hypothesis-h-d40d2659hypothesis-h-d40d2659→analysis-SDA-2026-04-01-gap-00analysis-SDA-2026-04-01-gap-00→hypothesis-h-5ff6c5cahypothesis-h-5ff6c5ca→analysis-SDA-2026-04-01-gap-00analysis-SDA-2026-04-01-gap-00→hypothesis-h-57862f8ahypothesis-h-57862f8a→analysis-SDA-2026-04-01-gap-00analysis-SDA-2026-04-01-gap-00→hypothesis-h-aa8b4952hypothesis-h-aa8b4952→analysis-SDA-2026-04-01-gap-00
🗣 Debate History2 sessions
gap_analysisWhat are the mechanisms underlying selective vulnerability of entorhinal cortex layer ii neurons in ad?r4q=0.922026-04-01
gap_analysisWhat are the mechanisms underlying selective vulnerability of entorhinal cortex layer ii neurons in ad?r4q=0.922026-04-01+0.000
This artifact has no version history yet.
Linked Artifacts (5618)
🧬 Related Hypotheses — same target / disease (20)
Tau/MAP6 antagonism in neurodegeneration progression
Score: 0.650 · Target: MAP6 · neurodegeneration
Activity-dependent MAP6 scaffolding at synapses
Score: 0.600 · Target: MAP6 · neurodegeneration
Domain boundary cross-talk hypothesis
Score: 0.600 · Target: MAP6 · neurodegeneration
MAP6-mediated microtubule stabilization as therapeutic target
Score: 0.500 · Target: MAP6 · neurodegeneration
Gut Microbiome Remodeling to Prevent Systemic NLRP3 Priming in Neurodegeneration
Score: 0.924 · Target: NLRP3, CASP1, IL1B, PYCARD · neurodegeneration
APOE-Dependent Autophagy Restoration
Score: 0.895 · Target: MTOR · neurodegeneration
Hypothesis 4: Metabolic Coupling via Lactate-Shuttling Collapse
Score: 0.895 · Target: SLC16A1, SLC16A7, LDHA, PDHA1 · neurodegeneration
p38α Inhibitor and PRMT1 Activator Combination to Restore Physiological TDP-43 Phosphoryla
Score: 0.895 · Target: MAPK14/PRMT1 · neurodegeneration
SIRT1-Mediated Reversal of TREM2-Dependent Microglial Senescence
Score: 0.893 · Target: SIRT1 · neurodegeneration
TREM2-Mediated Astrocyte-Microglia Crosstalk in Neurodegeneration
Score: 0.892 · Target: TREM2 · neurodegeneration
Optimized Temporal Window for Metabolic Boosting Therapy Determines Success of Microglial
Score: 0.887 · Target: IFNG · neurodegeneration
TREM2-APOE Axis Dissociation for Selective DAM Activation
Score: 0.886 · Target: TREM2-APOE axis · neurodegeneration
Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation
Score: 0.882 · Target: HCRTR1/HCRTR2 · neurodegeneration
Complement Cascade Inhibition Synaptic Protection
Score: 0.867 · Target: — · neurodegeneration
TREM2 R47H Variant-Driven Metabolic Dysfunction as the Primary Trigger for Failed DAM Tran
Score: 0.862 · Target: NAMPT · neurodegeneration
H6: Aberrant eIF2α Phosphorylation Creates Stalled Translation State
Score: 0.856 · Target: EIF2S1, EIF2AK3/PERK, PPP1R15B, EIF2B · neurodegeneration
Senescent Cell ASM-Complement Cascade Intervention
Score: 0.852 · Target: SMPD1 · neurodegeneration
Prime Editing Precision Correction of APOE4 to APOE3 in Microglia
Score: 0.850 · Target: APOE · neurodegeneration
TREM2-Deficient Microglia as Drivers of Amyloid Plaque Toxicity in Alzheimer's Disease
Score: 0.847 · Target: TREM2 · neurodegeneration
TYROBP (DAP12) Conditional Antagonism for Early-Stage Neuroprotection
Score: 0.844 · Target: TYROBP · neurodegeneration
Reference URLs
Embed this artifact
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
HTML iframe
<iframe src="http://scidex.ai/artifact/hypothesis-h-e12109e3?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
Markdown link
[Tau-Independent Microtubule Stabilization via MAP6 Enhancement](http://scidex.ai/artifact/hypothesis-h-e12109e3)
Direct URL
http://scidex.ai/artifact/hypothesis-h-e12109e3
Preview
🔄 Adjacent Artifacts
Recommended based on your interests
💬 Discussion
Loading comments...
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.